U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06954233) titled 'Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testictular Cancer' on April 24.
Brief Summary: This study aims to evaluate how retroperitoneal lymph node dissection (RPLND), a surgical treatment for testicular cancer, may affect urinary and sexual functions in men. RPLND involves the removal of lymph nodes from the abdominal area and is sometimes necessary in patients who are not eligible for chemotherapy or who have residual disease after chemotherapy. While this surgery is known to carry a risk of affecting ejaculation, its potential impact on other areas such as urination or erection is not well under...